SHC012
MISSION® pLKO.1-puro-CMV-TagRFP™ Positive Control Plasmid DNA
Contains a gene encoding TagRFP
동의어(들):
MISSION® Control Vectors
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
Concentration:
500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)
Quality Level
product line
MISSION®
concentration
500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)
shipped in
dry ice
storage temp.
−20°C
General description
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, we recommend producing self-inactivating replication incompetent viral particles in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The CMV-TagRFP Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Application
To see more application data, protocols, vector maps visit sigma.com/shrna.
The MISSION TagRFP Control Vector is an 8594 base pair lentivirus plasmid vector that contains a gene encoding TagRFP, under the control of the CMV promoter. The CMV-TagRFP Control Vector is useful as a positive control in experiments using the MISSION shRNA library clones.
The MISSION TagRFP Control Vector is an 8594 base pair lentivirus plasmid vector that contains a gene encoding TagRFP, under the control of the CMV promoter. The CMV-TagRFP Control Vector is useful as a positive control in experiments using the MISSION shRNA library clones.
Legal Information
TagRFP is a trademark of Evrogen Co.
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
저장 등급
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
문서
When shRNA is delivered using lentiviral vectors, the sequence encoding the shRNA is integrated into the genome and the knockdown effect is passed on to daughter cells, continuing gene silencing.
관련 콘텐츠
pLKO.1-puro-CMV-TagRFP Vector Backbone
Chi Huu Nguyen et al.
Scientific reports, 9(1), 9139-9139 (2019-06-27)
Acute myeloid leukemia (AML) is a heterogeneous disease with respect to its genetic and molecular basis and to patients´ outcome. Clinical, cytogenetic, and mutational data are used to classify patients into risk groups with different survival, however, within-group heterogeneity is
Chi Huu Nguyen et al.
Cell death & disease, 10(12), 944-944 (2019-12-12)
Ecotropic virus integration site 1 (EVI1), whose overexpression characterizes a particularly aggressive subtype of acute myeloid leukemia (AML), enhanced anti-leukemic activities of all-trans retinoic acid (atRA) in cell lines and patient samples. However, the drivers of leukemia formation, therapy resistance
국제 무역 품목 번호
| SKU | GTIN |
|---|---|
| SHC012 | 04061826600443 |